Short answer
Adaptive Biotechnologies Corp (ADPT) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $84M (down 10.7% year over year) with net income of $3M.
Q3 2026 key financials · XBRL
- Revenue
- $84M
- −10.7% YoY · +17.3% QoQ
- Net income
- $3M
- −69.9% YoY · +107.2% QoQ
- Operating margin
- -0.5%
- EPS (diluted)
- $0.02
- −71.4% YoY · +108.0% QoQ
Source: XBRL data from the Adaptive Biotechnologies Corp (ADPT) Q3 2026 10-Q on SEC EDGAR. USD.
Adaptive Biotechnologies Corp Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $83.9M, down $10.1M or 11% YoY
- Operating margin (0.5%) vs 10.9% YoY, net income $2.9M vs $9.5M
- Best segment MRD: revenue $72.6M, Adjusted EBITDA $15.1M vs $7.0M
- Worst segment Immune Medicine: revenue $11.3M vs $37.2M, Adjusted EBITDA $3.2M vs $24.1M
- Cash, equivalents and securities $400.2M vs $240.2M, nine-month operating cash use $6.3M vs $48.0M; near-term Immune Medicine revenue expected to decrease
Risk Factors
- No material changes to risk factors from the February 26, 2026 10-K or August 4, 2026 10-Q
- Business risk: Rapidly changing operating environment could materially affect results
- Liquidity risk: Combined risks could adversely affect financial condition or liquidity
- Market risk: Adverse developments could reduce the value of common stock
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Adaptive Biotechnologies Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.